ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
84.19
0.78%
US Dollar vs AUD
1.53183
0.06%
Bitcoin
58,790.01
0.95%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Argen X SE (ARGX)

  7. Argen X SE (ARGX) News

ARGX

Argen X (ARGX)

Argen X SE
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ARGX
DateTimeSourceHeadlineSymbolCompany
02/05/202415:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024EU:ARGXArgen X SE
16/04/202415:00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseEU:ARGXArgen X SE
27/03/202417:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseEU:ARGXArgen X SE
27/03/202407:00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024EU:ARGXArgen X SE
26/03/202417:00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
08/03/202408:01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingEU:ARGXArgen X SE
29/02/202417:00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateEU:ARGXArgen X SE
26/02/202417:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
22/02/202417:00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024EU:ARGXArgen X SE
20/02/202417:00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
18/01/202417:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisEU:ARGXArgen X SE
08/01/202417:00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesEU:ARGXArgen X SE
02/01/202417:00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceEU:ARGXArgen X SE
20/12/202317:00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusEU:ARGXArgen X SE
28/11/202317:00GlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaEU:ARGXArgen X SE
16/11/202323:40GlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisEU:ARGXArgen X SE
01/11/202317:00GlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsEU:ARGXArgen X SE
01/11/202317:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
31/10/202317:00GlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateEU:ARGXArgen X SE
24/10/202316:00GlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023EU:ARGXArgen X SE
21/09/202315:00GlobeNewswire Inc.argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia GravisEU:ARGXArgen X SE
15/09/202315:00GlobeNewswire Inc.argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia GravisEU:ARGXArgen X SE
30/08/202315:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesEU:ARGXArgen X SE
27/07/202315:00GlobeNewswire Inc.argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business UpdateEU:ARGXArgen X SE
25/07/202306:30GlobeNewswire Inc.argenx announces closing of global offeringEU:ARGXArgen X SE
20/07/202315:00GlobeNewswire Inc.argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023EU:ARGXArgen X SE
20/07/202307:58GlobeNewswire Inc.argenx announces full exercise of underwriters’ option to purchase additional ADSsEU:ARGXArgen X SE
19/07/202311:30GlobeNewswire Inc.argenx raises $1.1 billion in gross proceeds in a global offeringEU:ARGXArgen X SE
18/07/202306:01GlobeNewswire Inc.argenx announces launch of proposed global offeringEU:ARGXArgen X SE
17/07/202315:00GlobeNewswire Inc.argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating PolyneuropathyEU:ARGXArgen X SE
 Showing the most relevant articles for your search:EU:ARGX

Your Recent History

FTSE
UKX
FTSE 100
ASX
XFL
S&P ASX 50
ASX
QBE
QBE Insurance
NASDAQ
NVDA
NVIDIA
FX
AUDCAD
AUD vs CAD
ASX
XTO
S&P ASX 100
ASX
CBA
Commonwealth Bank Of Aus...
COIN
BTCUSD
Bitcoin
ASX
NCM
Newcrest Mining
NYSE
NKE
Nike
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
ASX
NAB
National Australia Bank
FX
EURAUD
Euro vs AUD
FX
AUDUSD
AUD vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved